Scholar Rock Holding Corporation

Scholar Rock is delivering muscle-targeted breakthroughs to transform the treatment of spinal muscular atrophy (SMA) and other rare neuromuscular diseases where muscle atrophy remains a critical unmet need. Scholar Rock intends to commercialize ISEMBYLD (apitegromab-mstn) globally, beginning in the U.S. for individuals living with SMA who are 2 years of age and older and currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

Current securities

1. 4 filingSep 23, 2026
2. Regulation FD DisclosureSep 15, 2026
3. Regulation FD Disclosure · Other EventsSep 14, 2026
4. SCHEDULE 13G/A filingAug 14, 2026
5. Other EventsAug 6, 2026